Increased GP88 expression has been reported in breast cancer, brain tumors, non-small cell lung cancer, ovarian cancer, renal carcinoma, hepatocellular carcinoma, prostate cancer, colorectal cancer and hematological cancers [22,24,25,26,27,28,29,30]. Here, GRN is linked to prostate carcinoma.